ATE403862T1 - Diagnostisches verfahren für nierenkrankheiten in menschen - Google Patents

Diagnostisches verfahren für nierenkrankheiten in menschen

Info

Publication number
ATE403862T1
ATE403862T1 AT00928274T AT00928274T ATE403862T1 AT E403862 T1 ATE403862 T1 AT E403862T1 AT 00928274 T AT00928274 T AT 00928274T AT 00928274 T AT00928274 T AT 00928274T AT E403862 T1 ATE403862 T1 AT E403862T1
Authority
AT
Austria
Prior art keywords
kidney disease
iron
humans
human beings
diagnostic procedure
Prior art date
Application number
AT00928274T
Other languages
English (en)
Inventor
Sudhir Shah
Original Assignee
Shiva Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiva Biomedical Llc filed Critical Shiva Biomedical Llc
Application granted granted Critical
Publication of ATE403862T1 publication Critical patent/ATE403862T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00928274T 1999-04-23 2000-04-21 Diagnostisches verfahren für nierenkrankheiten in menschen ATE403862T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13090399P 1999-04-23 1999-04-23
US13090899P 1999-04-23 1999-04-23

Publications (1)

Publication Number Publication Date
ATE403862T1 true ATE403862T1 (de) 2008-08-15

Family

ID=26828952

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00928274T ATE403862T1 (de) 1999-04-23 2000-04-21 Diagnostisches verfahren für nierenkrankheiten in menschen

Country Status (11)

Country Link
EP (1) EP1173757B1 (de)
JP (2) JP2002543386A (de)
AT (1) ATE403862T1 (de)
AU (1) AU4653400A (de)
CA (1) CA2371242A1 (de)
CY (1) CY1108468T1 (de)
DE (1) DE60039756D1 (de)
DK (1) DK1173757T3 (de)
ES (1) ES2311456T3 (de)
PT (1) PT1173757E (de)
WO (1) WO2000065346A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017650A2 (en) * 2004-08-06 2006-02-16 Shiva Biomedical, Llc Iron chelators for treating radiocontrast-associated renal dysfunction
US20080085563A1 (en) * 2006-10-10 2008-04-10 Idexx Laboratories, Inc. Detection of Gadolinium Chelates
ES2937273T3 (es) * 2015-01-07 2023-03-27 Nottingham Univ Hospitals Nhs Trust Biomarcadores relacionados con la función renal y métodos que implican su uso

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039709A (en) * 1989-11-30 1991-08-13 Basf Aktiengesellschaft Anipamil for the treatment of chronic renal failure
DE4008323A1 (de) * 1990-03-15 1991-09-19 Knoll Ag Verwendung von gallopamil zur herstellung von arzneiimitteln zur behandlung von akutem nierenversagen
RU2038598C1 (ru) * 1992-07-06 1995-06-27 Шапиро Светлана Борисовна Способ уринодиагностики заболеваний почек
EP1112088B1 (de) * 1998-09-08 2010-10-27 Henry Ford Health System Verfahren zum Nachweis von Bindegewebswachstumsfaktor zur Diagnose von Nierkrankheiten

Also Published As

Publication number Publication date
WO2000065346A9 (en) 2002-06-06
DE60039756D1 (de) 2008-09-18
JP2010248242A (ja) 2010-11-04
ES2311456T3 (es) 2009-02-16
PT1173757E (pt) 2008-11-11
EP1173757A1 (de) 2002-01-23
EP1173757B1 (de) 2008-08-06
CY1108468T1 (el) 2014-04-09
CA2371242A1 (en) 2000-11-02
AU4653400A (en) 2000-11-10
WO2000065346A1 (en) 2000-11-02
JP2002543386A (ja) 2002-12-17
DK1173757T3 (da) 2008-12-08

Similar Documents

Publication Publication Date Title
Yao et al. Microdialysis sampling and monitoring of uric acid in vivo by a chemiluminescence reaction and an enzyme on immobilized chitosan support membrane
ATE540976T1 (de) Antikörper zur inhibierung der blutgerinnung und verfahren zur deren verwendung
UA87979C2 (ru) Человеческое моноклональное антитело, которое нейтрализует моноцитарный хемоатрактантный белок (мср-1)
ATE442592T1 (de) Detektion und/oder beobachtung von synuclein- assoziierten krankheiten
BR8807559A (pt) Processo para reduzir danos nos tecidos que ocorrem em um local inflamatorio em qualquer parte do corpo humano e para reduzir danos por inflamacao miocardiana em um paciente humano
PT1097719E (pt) Compostos para o tratamento de disfuncao sexual feminina
IL138788A0 (en) Method and kit for the transdermal determination of analyte concentration in blood
EA200100261A1 (ru) Производные тиазолиновой кислоты (варианты) и способ лечения болезненного состояния (варианты)
CY1108468T1 (el) Διαγνωση νεφρικων νοσων στον ανθρωπο
WO2003092601A3 (en) A method for detecting lysosomal storage diseases
WO2004039244A3 (en) Methods and kits for diagnosing tumorigenicity
EP1162457A3 (de) Vielfach-Koagulationstestsystem und Verfahren zu seiner Anwendung
ATE537823T1 (de) Verfahren zur behandlung von präeklampsie beim menschen mit resibufagenin
Mishra et al. Validation of a sensitive enzymeimmunoassay for 13, 14-dihydro-15-keto-PGF2α in buffalo plasma and its application for reproductive health status monitoring
WO1999063116A3 (en) Use of prothymosin in the diagnosis and treatment of endometriosis
WO2002082092A3 (de) Bestimmung der wirksamen parathormon-aktivität in einer probe
JP2002543386A5 (de)
UA38074A (uk) Спосіб визначення мембраностабілізуючої функції організму і пристрій для його здійснення
JPH0378654A (ja) 血管障害判定法
RU2003133784A (ru) Способ оценки эффективности детоксикационного эффекта плазмафереза
RU2000126363A (ru) Способ диагностики гнойно-некротических осложнений при панкреонекрозе
WO2002049502A3 (en) Methods for diagnosing and treating pediatric neoplasms
WO2000047997A3 (en) Anti-lamin antibodies, endogenous inhibitors of thrombosis
UA38056A (uk) Спосіб прогнозування та контролю ефективності лікування гіпертонічної хвороби
UA36590C2 (uk) Спосіб раннього прогнозування ефективності лікування хворих на алкогольну залежність за методом о.р. довженка

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1173757

Country of ref document: EP